Identification of cytochrome P450s involved in the metabolism of arachidonic acid in human platelets

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 4, 2013, Pages 227-234

  Jarrar, Yazun B ^a   Cho, Sun Ah ^a   Oh, Kyung Suk ^a   Kim, Dong Hyun ^a   Shin, Jae Gook ^a,b   Lee, Su Jun ^a  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Arachidonic acid; Cytochrome P450; Metabolism; Platelet

Indexed keywords

17 OCTADECYNOIC ACID; ALPHA NAPHTHOFLAVONE; ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2J2; CYTOCHROME P450 2U1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4A11; CYTOCHROME P450 4F2; CYTOCHROME P450 5A1; MESSENGER RNA; PROADIFEN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME METABOLISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ARACHIDONIC ACID; CYTOCHROME P450; METABOLISM; PLATELET;

ADULT; ARACHIDONIC ACIDS; BLOOD PLATELETS; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS, UNSATURATED; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84884531915     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.06.008     Document Type: Article

References (51)

1. Spriet I., Meersseman W., de Hoon J., von Winckelmann S., Wilmer A., Willems L. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009, 35:603-612.
2. Canaparo R., Finnstrom N., Serpe L., Nordmark A., Muntoni E., Eandi M., Rane A., Zara G.P. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin. Exp. Pharmacol. Physiol. 2007, 34:1138-1144.
3. Bieche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., Beaune P., de Waziers I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 2007, 17:731-742.
4. Hanaoka T., Yamano Y., Pan G., Hara K., Ichiba M., Zhang J., Zhang S., Liu T., Li L., Takahashi K., Kagawa J., Tsugane S. Cytochrome P450 1B1 mRNA levels in peripheral blood cells and exposure to polycyclic aromatic hydrocarbons in Chinese coke oven workers. Sci. Total. Environ. 2002, 296:27-33.
5. Horiike N., Abe M., Kumagi T., Hiasa Y., Akbar S.M., Michitaka K., Onji M. The quantification of cytochrome P-450 (CYP 3A4) mRNA in the blood of patients with viral liver diseases. Clin. Biochem. 2005, 38:531-534.
6. Hannon-Fletcher M.P., Barnett Y.A. Lymphocyte cytochrome P450 expression: inducibility studies in male Wistar rats. Br. J. Biomed. Sci. 2008, 65:1-6.
7. Rosolowsky M., Falck J.R., Campbell W.B. Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Biochim. Biophys. Acta 1996, 1300:143-150.
8. Siest G., Jeannesson E., Marteau J.B., Samara A., Marie B., Pfister M., Visvikis-Siest S. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab. Dispos. 2008, 36:182-189.
9. Kiso Y. Pharmacology in health foods: effects of arachidonic acid and docosahexaenoic acid on the age-related decline in brain and cardiovascular system function. J. Pharmacol. Sci. 2011, 115:471-475.
10. Williams J.M., Murphy S., Burke M., Roman R.J. 20-Hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 2010, 56:336-344.
11. Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem. 2000, 275:4118-4126.
12. Pearson T., Warren A.Y., Barrett D.A., Khan R.N. Detection of EETs and HETE-generating cytochrome P-450 enzymes and the effects of their metabolites on myometrial and vascular function. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E647-656.
13. Devos A., Lino Cardenas C.L., Glowacki F., Engels A., Lo-Guidice J.M., Chevalier D., Allorge D., Broly F., Cauffiez C. Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation. Prostaglandins Leukot. Essent. Fatty Acids 2010, 83:105-110.
14. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther. 2008, 118:18-35.
15. Zhu Y., Schieber E.B., McGiff J.C., Balazy M. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 1995, 25:854-859.
16. Tsai I.J., Croft K.D., Puddey I.B., Beilin L.J., Barden A. 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am. J. Physiol. Heart. Circ. Physiol. 2011, 300:H1194-1200.
17. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002, 82:131-185.
18. Mustard J.F., Kinlough-Rathbone R.L., Packham M.A. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol. 1989, 169:3-11.
19. Panes O., Matus V., Saez C.G., Quiroga T., Pereira J., Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007, 109:5242-5250.
20. Stratz C., Nuhrenberg T.G., Binder H., Valina C.M., Trenk D., Hochholzer W., Neumann F.J., Fiebich B.L. Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNA. Thromb. Haemost. 2012, 107:634-641.
21. Lee S.J., Lee S.S., Jung H.J., Kim H.S., Park S.J., Yeo C.W., Shin J.G. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab. Dispos. 2009, 37:1464-1470.
22. Ozeki Y., Nagamura Y., Ito H., Unemi F., Kimura Y., Igawa T., Kambayashi J., Takahashi Y., Yoshimoto T. An anti-platelet agent, OPC-29030, inhibits translocation of 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid production in human platelets. Br. J. Pharmacol. 1999, 128:1699-1704.
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
24. Kennedy S.W., Lorenzen A., James C.A., Collins B.T. Ethoxyresorufin-O-deethylase and porphyrin analysis in chicken embryo hepatocyte cultures with a fluorescence multiwell plate reader. Anal. Biochem. 1993, 211:102-112.
25. Leoncini G., Bruzzese D., Signorello M.G. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J. Thromb. Haemost. 2006, 4:209-216.
26. Wang M.Z., Saulter J.Y., Usuki E., Cheung Y.L., Hall M., Bridges A.S., Loewen G., Parkinson O.T., Stephens C.E., Allen J.L., Zeldin D.C., Boykin D.W., Tidwell R.R., Parkinson A., Paine M.F., Hall J.E. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab. Dispos. 2006, 34:1985-1994.
27. Yue H., Jansen S.A., Strauss K.I., Borenstein M.R., Barbe M.F., Rossi L.J., Murphy E. A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat brain tissue. J. Pharm. Biomed. Anal. 2007, 43:1122-1134.
28. Xu X., Zhang X.A., Wang D.W. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv. Drug Deliv. Rev. 2011, 63:597-609.
29. Theken K.N., Deng Y., Kannon M.A., Miller T.M., Poloyac S.M., Lee C.R. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab. Dispos. 2011, 39:22-29.
30. Mitra R., Guo Z., Milani M., Mesaros C., Rodriguez M., Nguyen J., Luo X., Clarke D., Lamba J., Schuetz E., Donner D.B., Puli N., Falck J.R., Capdevila J., Gupta K., Blair I.A., Potter D.A. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (+/-)-14,15-epoxyeicosatrienoic acid (EET). J. Biol. Chem. 2011, 286:17543-17559.
31. Kohagura K., Arima S., Endo Y., Chiba Y., Ito O., Abe M., Omata K., Ito S. Involvement of cytochrome P450 metabolites in the vascular action of angiotensin II on the afferent arterioles. Hypertens. Res. 2001, 24:551-557.
32. Imig J.D., Falck J.R., Inscho E.W. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br. J. Pharmacol. 1999, 127:1399-1405.
33. Heizer M.L., McKinney J.S., Ellis E.F. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 1991, 22:1389-1393.
34. Liu J.Y., Li N., Yang J., Qiu H., Ai D., Chiamvimonvat N., Zhu Y., Hammock B.D. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17017-17022.
35. Wu C.C., Schwartzman M.L. The role of 20-HETE in androgen-mediated hypertension. Prostaglandins Other Lipid Mediat. 2011, 96:45-53.
36. Seidegard J., DePierre J.W., Pero R.W. Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood. Cancer Res. 1984, 44:3654-3660.
37. Roth M.D., Marques-Magallanes J.A., Yuan M., Sun W., Tashkin D.P., Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am. J. Respir. Cell Mol. Biol. 2001, 24:339-344.
38. Williams J.S., Hopkins P.N., Jeunemaitre X., Brown N.J. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. J. Hypertens. 2011, 29:1913-1918.
39. Ward N.C., Tsai I.J., Barden A., van Bockxmeer F.M., Puddey I.B., Hodgson J.M., Croft K.D. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 2008, 51:1393-1398.
40. Koyama T., Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. Semin. Thromb. Hemost. 1998, 24:217-226.
41. Antoun J., Amet Y., Simon B., Dreano Y., Corlu A., Corcos L., Salaun J.P., Plee-Gautier E. CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett. 2006, 580:3361-3367.
42. Karlgren M., Miura S., Ingelman-Sundberg M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005, 207:57-61.
43. Dauchy S., Miller F., Couraud P.O., Weaver R.J., Weksler B., Romero I.A., Scherrmann J.M., De Waziers I., Decleves X. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem. Pharmacol. 2009, 77:897-909.
44. Wu S., Moomaw C.R., Tomer K.B., Falck J.R., Zeldin D.C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 1996, 271:3460-3468.
45. Spiecker M., Liao J. Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc. Med. 2006, 16:204-208.
46. Borgel J., Bulut D., Hanefeld C., Neubauer H., Mugge A., Epplen J.T., Holland-Letz T., Spiecker M. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc. Disord. 2008, 8:41.
47. Yang S.H., Lee M.G. Effects of cytochrome P450 (CYP) inducers and inhibitors on ondansetron pharmacokinetics in rats: involvement of hepatic CYP2D subfamily and 3A1/2 in ondansetron metabolism. J. Pharm. Pharmacol. 2008, 60:853-861.
48. Levova K., Moserova M., Kotrbova V., Sulc M., Henderson C.J., Wolf C.R., Phillips D.H., Frei E., Schmeiser H.H., Mares J., Arlt V.M., Stiborova M. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol. Sci. 2011, 121:43-56.
49. Hayashibara T., Yamada Y., Mori N., Harasawa H., Sugahara K., Miyanishi T., Kamihira S., Tomonaga M. Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem. Biophys. Res. Commun. 2003, 300:128-134.
50. Ts'ao C.H. Rough endoplasmic reticulum and ribosomes in blood platelets. Scand. J. Haematol. 1971, 8:134-140.
51. Ishikawa S., Manabe S., Wada O. Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Biochem. Pharmacol. 1986, 35:1787-1792.